PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions.

摘要: Purpose Somatostatin receptor (sstr) positive tumours vary widelyinuptakeofradiolabelled somatostatin(sst) analogues. This study determinates variability in lesion uptake of the glycosylated sst analogon N α -(1-deoxy-D-fructosyl)-N ɛ (2-[ 18 F]fluoropropionyl)-Lys 0 -Tyr 3 -octreotate (Gluc-Lys([ F] FP)-TOCA) and correlates it with size arterial perfusion as measured on computed tomography (CT). Methods Ten patients metastasized neuroendocrine carcinomas were investigated positron emission PET/CT (Biograph 16, Siemens, Germany). Lesion standardized values (SUVs) determined at ∼50 min post tracer injection according to a 60% isocontour volume interest around each lesion. enhancement phase (hounsfield units, HUs) derived from CT. Results 114 lesions upper abdomen had correlate both, PET Variability SUVs was high (SUVmean 22±13). Intraindividually, there sigmoid correlation between SUV diameter indicating partial effects. Residual ≥ 3c m (≥2.5 cm) ranged down about half (third) maximum remained unexplained by No HU found, neither intraindividually nor interindividually. Conclusion Partial effects major source intraindividual tumour uptake. Lesions below 2.5 cm should thus be used caution when performing dose calculations. In larger residual must considered; may due variable sstr2 expression tumours’ cell surfaces.